Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952521 | 0.81 | — | — | |
| SCHEMBL3074164 | 0.78 | LDHA (0.47) | TSHRKDM4ELDHASRR | |
| SCHEMBL28454856 | 0.78 | HDAC3 (0.39) | ALDH1A1KDM4EGAAL3MBTL1CTSK | |
| SCHEMBL15315158 | 0.77 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL8379955 | 0.77 | TDP1 (0.41) | TSHRALDH1A1L3MBTL1 | |
| Acetoacetic Acid SCHEMBL29569084 | 0.76 | TSHR (0.39) | TSHRALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL28797767 | 0.75 | GAA (0.48) | TSHRALDH1A1GAAL3MBTL1 | |
| SCHEMBL3827402 | 0.75 | CA1 (0.38) | CYP2D6L3MBTL1CTSK | |
| SCHEMBL1505049 | 0.75 | LDHA (0.38) | TSHRALDH1A1KDM4ECYP2D6LDHA | |
| SCHEMBL11734417 | 0.74 | FAAH (0.40) | TSHRALDH1A1GAAL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100349895-C | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2007-11-21 | — | — | CN | disclosed |
| CN-1759117-A | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | CN | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | TSHR 1549/4885ALDH1A1 328/4885KDM4E 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.